JP2013519705A5 - - Google Patents

Download PDF

Info

Publication number
JP2013519705A5
JP2013519705A5 JP2012553298A JP2012553298A JP2013519705A5 JP 2013519705 A5 JP2013519705 A5 JP 2013519705A5 JP 2012553298 A JP2012553298 A JP 2012553298A JP 2012553298 A JP2012553298 A JP 2012553298A JP 2013519705 A5 JP2013519705 A5 JP 2013519705A5
Authority
JP
Japan
Prior art keywords
amphetamine
pharmaceutical preparation
preparation according
prodrug
hours
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012553298A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013519705A (ja
Filing date
Publication date
Priority claimed from GBGB1002612.8A external-priority patent/GB201002612D0/en
Application filed filed Critical
Publication of JP2013519705A publication Critical patent/JP2013519705A/ja
Publication of JP2013519705A5 publication Critical patent/JP2013519705A5/ja
Pending legal-status Critical Current

Links

JP2012553298A 2010-02-16 2011-02-16 アンフェタミンおよびリスデキサンフェタミンを含む組成物 Pending JP2013519705A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1002612.8A GB201002612D0 (en) 2010-02-16 2010-02-16 Improvements in or relating to organic compounds
GB1002612.8 2010-02-16
PCT/EP2011/052295 WO2011101374A1 (en) 2010-02-16 2011-02-16 Compositions comprising amphetamin and lisdexamfetamine

Publications (2)

Publication Number Publication Date
JP2013519705A JP2013519705A (ja) 2013-05-30
JP2013519705A5 true JP2013519705A5 (enExample) 2014-03-27

Family

ID=42110793

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012553298A Pending JP2013519705A (ja) 2010-02-16 2011-02-16 アンフェタミンおよびリスデキサンフェタミンを含む組成物

Country Status (7)

Country Link
US (1) US8927608B2 (enExample)
EP (1) EP2536402B1 (enExample)
JP (1) JP2013519705A (enExample)
DK (1) DK2536402T3 (enExample)
ES (1) ES2547141T3 (enExample)
GB (1) GB201002612D0 (enExample)
WO (1) WO2011101374A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101495146B1 (ko) 2006-03-16 2015-02-24 트리스 파마 인코포레이티드 약물 - 이온교환 수지 복합체를 함유하는 변형 방출 제제
EP2592078A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
DK2884961T3 (en) 2012-08-15 2019-04-23 Tris Pharma Inc METHYLPHENIDATE TABLE WITH EXTENDED RELEASE
TWI641373B (zh) * 2013-07-25 2018-11-21 阿爾米雷爾有限公司 具有蕈毒鹼受體拮抗劑和β２腎上腺素受體促效劑二者之活性的２－胺基－１－羥乙基－８－羥基喹啉－２（１Ｈ）－酮衍生物之鹽
TW201517906A (zh) 2013-07-25 2015-05-16 Almirall Sa 含有ｍａｂａ化合物和皮質類固醇之組合
US11590228B1 (en) 2015-09-08 2023-02-28 Tris Pharma, Inc Extended release amphetamine compositions
JP2020516694A (ja) * 2017-04-10 2020-06-11 シャイアー ファーマシューティカルズ インコーポレイテッドＳｈｉｒｅ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． アンフェタミンプロドラッグを使用する治療方法
US12458592B1 (en) 2017-09-24 2025-11-04 Tris Pharma, Inc. Extended release amphetamine tablets
US11590081B1 (en) 2017-09-24 2023-02-28 Tris Pharma, Inc Extended release amphetamine tablets
AU2024227385A1 (en) * 2024-03-28 2025-10-16 Athena Pharmaceutiques Sas Lisdexamfetamine dimesylate orodispersible tablet and process for preparation thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6322819B1 (en) * 1998-10-21 2001-11-27 Shire Laboratories, Inc. Oral pulsed dose drug delivery system
US7659253B2 (en) * 2002-02-22 2010-02-09 Shire Llc Abuse-resistant amphetamine prodrugs
US6913768B2 (en) * 2002-09-24 2005-07-05 Shire Laboratories, Inc. Sustained release delivery of amphetamine salts
KR20050119106A (ko) * 2003-02-10 2005-12-20 샤이어 바이오켐 인코포레이티드 주의부족 과활성장애(ａｄｈｄ) 치료를 위한 에난티오머성암페타민 조성물
US20060204575A1 (en) * 2005-03-11 2006-09-14 Hengsheng Feng Amphetamine formulations
EP1865980A4 (en) * 2005-04-08 2009-11-11 Shire Llc ABUSEFUL AMPHETAMINE PRODRUGS
CA2641917A1 (en) * 2006-02-18 2007-08-23 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment of attention deficit hyperactivity disorder comprising flibanserin

Similar Documents

Publication Publication Date Title
JP2013519705A5 (enExample)
CA2923811C (en) Sublingual buprenorphine spray
JP2022060428A (ja) 経口送達と生物学的に同等である薬物動態を有する経皮送達システム
JP2005512995A5 (enExample)
JP7137618B2 (ja) 末梢神経障害性疼痛の治療に用いる少なくともアミトリプチリンを含む局所医薬組成物
US20140378521A1 (en) Use of nk-1 receptor antagonists in pruritus
MX2009002311A (es) Composiciones farmaceuticas para tratamiento de infecciones fungales.
NZ564381A (en) Transdermal method and patch for nausea comprising granisetron
JPWO2018070406A1 (ja) 水性貼付剤
JP2010529142A5 (enExample)
JP2017533956A (ja) 筋肉痛を含む病態の治療のための組合せ
JP4843824B2 (ja) 外用剤
JPWO2008120562A1 (ja) 帯状疱疹後神経痛治療用錠剤および帯状疱疹後神経痛の治療方法
BRPI0615769A2 (pt) formulações tópicas contendo o-desmetil venlafaxina (odv) ou seus sais
JP6163169B2 (ja) コカイン中毒者の処置におけるモダフィニルの使用
WO2024020598A1 (en) Methods of administering nalbuphine
WO2018002115A1 (en) Vortioxetine dosing regimes for fast onset of antidepressant effect
TW201625252A (zh) 藥物
RU2011140785A (ru) Фармацевтическая композиция для лечения диабета 2 типа
JP5460996B2 (ja) 眼科用剤
US20180153795A1 (en) Liquid buprenorphine formulations
US9867818B2 (en) Sublingual buprenorphine spray
JPWO2016052617A1 (ja) ナルフラフィン含有局所適用製剤
RU2023128802A (ru) Фармацевтическая композиция, содержащая селективный ингибитор jak3/jak1/tbk1, и ее медицинское применение
Fogarty et al. A Randomized, Double-blind, Placebo-controlled, Multi-center, Two-period Crossover Study To Investigate The Bronchodilatory Effect Of NVA237 50µg Inhaled Once Daily In Patients With COPD